Literature DB >> 31537267

2-Year Outcomes After Complete or Staged Procedure for Tetralogy of Fallot in Neonates.

Jill J Savla1, Jennifer A Faerber2, Yuan-Shung V Huang2, Theoklis Zaoutis2, Elizabeth Goldmuntz1, Steven M Kawut3, Laura Mercer-Rosa4.   

Abstract

BACKGROUND: There is ongoing debate about the best strategy to treat patients with tetralogy of Fallot who are symptomatic in the neonatal period.
OBJECTIVES: The aim of this study was to compare the outcomes of complete versus staged surgery (i.e., initial palliative procedure for possible later complete repair).
METHODS: A retrospective cohort study was performed using the Pediatric Health Information System database, including patients who underwent complete or staged tetralogy of Fallot repair prior to 30 days of age. The primary outcome was death during 2-year follow-up after the initial procedure. Inverse probability-weighted Cox and logistic regression models were used to examine the association between surgical approach group and mortality while accounting for patient- and hospital-level factors. Causal mediation analyses examined the role of intermediate variables.
RESULTS: A total of 2,363 patients were included (1,032 complete and 1,331 staged). There were 239 deaths. Complete neonatal repair was associated with a significantly higher risk for mortality during the 2-year follow-up period (hazard ratio: 1.51; 95% confidence interval: 1.05 to 2.06), between 7 and 30 days after the initial procedure (hazard ratio: 2.29; 95% confidence interval: 1.18 to 4.41), and during the initial hospital admission (odds ratio: 1.72; 95% confidence interval: 1.15 to 2.62). Post-operative cardiac complications were more common in the complete repair group and mediated the differences in 30-day and 2-year mortality.
CONCLUSIONS: Complete surgical repair for neonates with tetralogy of Fallot is associated with a significantly higher risk for early and 2-year mortality compared with the staged approach, after accounting for patient and hospital characteristics. Post-operative cardiac complications mediated these findings.
Copyright © 2019 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Pediatric Health Information System; cardiac surgery; causal mediation analysis; comparative effectiveness; congenital heart disease; inverse probability weighting

Mesh:

Year:  2019        PMID: 31537267      PMCID: PMC7155423          DOI: 10.1016/j.jacc.2019.05.057

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  41 in total

Review 1.  Neonatal complete correction of tetralogy of Fallot versus shunting and deferred repair: is the future of the right ventriculo-arterial junction at stake, and what of it?

Authors:  A Dodge-Khatami; I I Tulevski; J F Hitchcock; B A de Mol; G B Bennink
Journal:  Cardiol Young       Date:  2001-09       Impact factor: 1.093

2.  A simple unified approach for estimating natural direct and indirect effects.

Authors:  Theis Lange; Stijn Vansteelandt; Maarten Bekaert
Journal:  Am J Epidemiol       Date:  2012-07-10       Impact factor: 4.897

3.  Sensitivity Analysis in Observational Research: Introducing the E-Value.

Authors:  Tyler J VanderWeele; Peng Ding
Journal:  Ann Intern Med       Date:  2017-07-11       Impact factor: 25.391

4.  Establishing a high-risk neuroblastoma cohort using the Pediatric Health Information System Database.

Authors:  Richard Aplenc; Rochelle Bagatell; Ami V Desai; Marko Kavcic; Yuan-Shung Huang; Nicole Herbst; Brian T Fisher; Alix E Seif; Yimei Li; Sean Hennessy
Journal:  Pediatr Blood Cancer       Date:  2014-01-13       Impact factor: 3.167

5.  Tetralogy of Fallot: influence of surgical technique on survival and reoperation rate.

Authors:  A Boening; J Scheewe; J Paulsen; D Regensburger; H H Kramer; J Hedderich; J T Cremer
Journal:  Thorac Cardiovasc Surg       Date:  2001-12       Impact factor: 1.827

6.  Repair of tetralogy of Fallot in neonates and young infants.

Authors:  F A Pigula; P N Khalil; J E Mayer; P J del Nido; R A Jonas
Journal:  Circulation       Date:  1999-11-09       Impact factor: 29.690

7.  Outcomes, ICU Use, and Length of Stay in Chronically Ill Black and White Children on Medicaid and Hospitalized for Surgery.

Authors:  Jeffrey H Silber; Paul R Rosenbaum; Shawna R Calhoun; Joseph G Reiter; Alexander S Hill; Orit Even-Shoshan; William J Greeley
Journal:  J Am Coll Surg       Date:  2017-02-04       Impact factor: 6.113

8.  Propensity score weighting with multilevel data.

Authors:  Fan Li; Alan M Zaslavsky; Mary Beth Landrum
Journal:  Stat Med       Date:  2013-03-24       Impact factor: 2.373

Review 9.  The incidence of congenital heart disease.

Authors:  Julien I E Hoffman; Samuel Kaplan
Journal:  J Am Coll Cardiol       Date:  2002-06-19       Impact factor: 24.094

10.  Intermediate results after complete repair of tetralogy of Fallot in neonates.

Authors:  H A Hennein; R S Mosca; G Urcelay; D C Crowley; E L Bove
Journal:  J Thorac Cardiovasc Surg       Date:  1995-02       Impact factor: 5.209

View more
  2 in total

1.  Short-Term Outcomes of Epidural Analgesia in Minimally Invasive Esophagectomy for Esophageal Cancer: Nationwide Inpatient Data Study in Japan.

Authors:  Yuki Hirano; Hidehiro Kaneko; Takaaki Konishi; Hidetaka Itoh; Satoru Matsuda; Hirofumi Kawakubo; Kazuaki Uda; Hiroki Matsui; Kiyohide Fushimi; Hiroyuki Daiko; Osamu Itano; Hideo Yasunaga; Yuko Kitagawa
Journal:  Ann Surg Oncol       Date:  2022-08-12       Impact factor: 4.339

2.  Palliation Strategy to Achieve Complete Repair in Symptomatic Neonates with Tetralogy of Fallot.

Authors:  Mark A Law; Andrew C Glatz; Jennifer C Romano; Paul J Chai; Christopher E Mascio; Christopher J Petit; Courtney E McCracken; Michael S Kelleman; George T Nicholson; Jeffery J Meadows; Jeffrey D Zampi; Shabana Shahanavaz; Sarosh P Batlivala; Joelle Pettus; Amy L Pajk; Kristal M Hock; Bryan H Goldstein; Athar M Qureshi
Journal:  Pediatr Cardiol       Date:  2022-04-05       Impact factor: 1.838

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.